Sign in

    Mary Kate Davis

    Research Analyst at Bank of America

    No credible or verifiable professional profile for Mary Kate Davis as an analyst at Bank of America was found. Extensive search revealed no public LinkedIn profile, industry analyst platform results, or financial press recognition matching these specifics. As of now, there is no record of her coverage universe, job title, performance metrics, career history, or professional credentials in public sources.

    Mary Kate Davis's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership

    Mary Kate Davis's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership • Q3 2025

    Question

    Mary Kate Davis, on for David Lebowitz, asked how plozasiran addresses the unmet clinical need in familial chylomicronemia syndrome (FCS) and what physician feedback has been ahead of the potential launch.

    Answer

    SVP Andy Davis explained that plozasiran meets a critical need by providing deep triglyceride reduction and being the only agent in a Phase 3 trial to show a statistically significant reduction in acute pancreatitis risk. He also noted the convenient quarterly dosing as a key benefit for patients.

    Ask Fintool Equity Research AI

    Mary Kate Davis's questions to Editas Medicine (EDIT) leadership

    Mary Kate Davis's questions to Editas Medicine (EDIT) leadership • Q2 2024

    Question

    Mary Kate Davis asked for the company's perspective on future intellectual property (IP) licensing opportunities.

    Answer

    CFO Erick Lucera stated that Editas believes it has a very strong foundational IP position and is open to creating bespoke licensing structures with a range of companies. He highlighted this as a potential source of non-dilutive capital, noting a 'high double-digit number' of external programs are in development using technology that may require a license.

    Ask Fintool Equity Research AI